R&D News | pharmaphorum

News

Phase 3 wins put Dermavant closer to filing Otezla rival tap...

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of

News

Moderna’s COVID vaccine works in older people, according to ...

Moderna has said that its coronavirus vaccine stimulated an immune response in older people in phase 1 trials, suggesting that the jab is effective in the age groups most susceptible to COVID-19

News

Chasing Regeneron, AZ starts trials of its COVID-19 antibody...

The first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that are being developed to both treat and prevent coronavirus infec

News

Blow for Novartis as PD-1 drug spartalizumab flunks trial

Novartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed a phase 3 trial in skin cancer.

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Pfizer/BioNTech say COVID-19 jab on track for approval by ye...

Pfizer and BioNTech have said their COVID-19 vaccine could be ready for regulators to review by October and approved by the end of the year after releasing more favourable data from an earl

News

BioMarin files achondroplasia drug after rejection for haemo...

US biotech BioMarin has hit back with a filing for a rare disease drug, after suffering what was described by analysts as a “major setback” when the FDA rejected its gene therapy for haemop

Phase 3 wins put Dermavant closer to filing Otezla rival tap...

Moderna’s COVID vaccine works in older people, according to ...

Chasing Regeneron, AZ starts trials of its COVID-19 antibody...

Blow for Novartis as PD-1 drug spartalizumab flunks trial

Pfizer/BioNTech say COVID-19 jab on track for approval by ye...

BioMarin files achondroplasia drug after rejection for haemo...

Why everyone should care about longevity, with Boyang Wang

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks